Metropolis Healthcare has introduced three specialised metabolic health packages under its TruHealth portfolio. Designed for individuals preparing for or undergoing GLP-1–based therapies for diabetes, obesity and related metabolic conditions. These packages provide stage-specific assessments that enhance clinical decision-making and promote long-term metabolic safety.
Rising Metabolic Disorders Drive Need for Better Monitoring
India continues to experience a sharp rise in metabolic disorders such as early-onset obesity, insulin resistance, fatty liver disease and elevated cardiovascular risk. With GLP-1 agonists becoming a preferred therapy for weight management and glycaemic control, consistent metabolic tracking has become essential. Metropolis’ in-house data shows a steady rise in abnormal metabolic markers across major cities. This trend underscores the need for robust, clinically designed monitoring frameworks.
Scientifically Curated GLP-1 Packages for Every Stage
To meet this growing demand, Metropolis has launched three structured and scientifically curated test packages in its GLP-1 series:
• TruHealth GLP-1 Ready
• TruHealth GLP-1 Monitor
• TruHealth GLP-1 Monitor (3-Pack Subscription)
Each offering is tailored to address distinct pre-therapy, ongoing therapy and post-therapy monitoring needs.
TruHealth GLP-1 Ready: Comprehensive Pre-Therapy Assessment
TruHealth GLP-1 Ready provides a detailed baseline evaluation of an individual’s metabolic status before initiating GLP-1 or any advanced weight-management or diabetes treatment. It assesses:
– Glucose–insulin balance
– Lipid and cardiac risk markers
– Liver and kidney health
– Essential nutritional indicators
The package also includes vitals and an ECG to offer clinicians a holistic view of pre-therapy fitness.
TruHealth GLP-1 Monitor: Tracking Therapy Response
For individuals already on GLP-1 therapy, TruHealth GLP-1 Monitor offers a focused biochemical monitoring framework. It tracks evolving metabolic biomarkers and detects early signs of deficiencies or organ-related changes. It also supports clinicians with timely, data-driven insights to optimise treatment decisions.
Longitudinal Monitoring Through Subscription
To improve continuity of care, the TruHealth GLP-1 Monitor (3-Pack Subscription) provides structured evaluations at recommended intervals. This gives patients and clinicians a clear, longitudinal view of metabolic progress. It ensures that interventions remain precise, responsive and aligned with long-term therapeutic goals.
Leaders Emphasise Need for Diagnostic Support in GLP-1 Care
Surendran Chemmenkotil, Managing Director of Metropolis Healthcare Limited, highlighted the importance of structured diagnostics. He said, “As GLP-1 therapies gain traction across India, it is increasingly evident that they must be supported by a reliable diagnostic framework. Many individuals start or continue treatment without clear insight into their metabolic status or how their body is responding. These specialised GLP-1 packages address that gap by offering dependable, stage-appropriate assessments that enhance clinical decision-making. Our focus is on making metabolic monitoring accessible and meaningful, enabling safer and more informed care for every patient on a GLP-1 journey.”
Designed With Scientific Precision
As reported by Pharmabiz, Dr. Kirti Chadha, Chief Scientific and Innovation Officer at Metropolis Healthcare Limited, underscored the scientific rigor behind the offering. She said, “Developing meaningful GLP-1 diagnostics requires scientific precision, not just broader test menus. All three packages have been designed through a rigorous test-selection framework aligned with clinical evidence and physician protocols. They are powered by high-sensitivity platforms and robust validation systems. This ensures that every parameter included delivers real clinical value—whether assessing metabolic balance, therapeutic response or nutritional status. By emphasising relevance, depth and quality, the TruHealth GLP-1 series offers clinicians reliable insights to guide safe, effective and personalised care.”